We applied dipole modeling and brain distributed source analysis to find current sources comprising spikes and slow waves of polyspike and wave complexes (PSWC) in patients with juvenile myoclonic epilepsy (JME). The dipoles were localized in frontal, parietal and temporal lobes. The frontal dipoles were clustered in the frontal medial gyrus and fronto-orbital region. A midsagittal frontal current source was observed using brain distributed source analysis in all patients. When the slow wave was analyzed, multiple sources in different cortical regions were detected using dipole modeling and brain distributed analysis. These results show pre-frontal medial current sources corresponding to spikes and many diffuse sources in cortical regions corresponding to wave components of PSWC in patients with JME.

A sixty-two-year-old white woman with a 14.5 cm (145 mm) silent giant left atrial enlargement secondary probably to rheumatic heart disease is presented. Aside from mild progressive shortness of breath during the past year, the patient had been asymptomatic all her life. Her clinical picture was manifested for the first time by syncope secondary to slow atrial fibrillation, for which a permanent pacemaker was required. The correct diagnosis of the enlarged chamber was not possible through the routine chest roentgenogram. In this case, the echocardiogram, nuclear angiogram, and computed tomography were the pertinent studies needed to reach the diagnosis.

No abstract

No abstract

No abstract

The precision between dipole Brain Electric Source Analysis (BESA) and brain distributed Variable Resolution Electromagnetic Tomography (VARETA) models for the localization of brain sources of interictal epileptiform discharges in patients with partial complex epilepsy was compared. The localization of brain sources calculated with dipole analysis and variable resolution electromagnetic tomography in 20 interictal recordings was analyzed. The origin of the dipoles was temporal in 18 cases, frontal in 1 and occipital in another. One dipole was enough in 7 cases, whereas two dipoles were necessary in 13 cases. The localization of paroxysmal activity was the same with BESA and VARETA in 17 patients. BESA and VARETA are useful methods for EEG sources analysis; BESA has more precision for the localization of punctate epileptogenic regions, and VARETA provides more information concerning the extension of the epileptic zone.

For the past 6 years we used daily injection of luteinizing hormone-releasing hormone (LH-RH) agonists to treat patients with advanced prostate carcinoma. In this study we determined the hormonal response of the pituitary-testicular axis over a 2-month period and evaluated the safety and tolerance of the single intramuscular administration of sustained-release formulations of D-Trp-6-LH-RH microcapsules designed to release 50, 100, or 200 micrograms/day for over 1 month. Serum levels of LH, testosterone, and D-Trp-6-LH-RH were measured by RIA for up to 60 days in 10 patients with advanced prostatic carcinoma who had not received any previous drug therapy. After the administration of the microcapsules there was a biphasic increase in D-Trp-6-LH-RH serum levels. The maximal peak was obtained between 1 and 3 hr, and a second peak occurred between weeks 4 and 6. LH levels increased initially, with a maximal peak at 60 min, and elevated serum LH values persisted for more than 24 hr. LH levels began to fall on the second day, reaching subnormal values after 1 week. Serum testosterone rose during the first week and fell subsequently to less than 100 ng/dl. A rebound in LH and testosterone was seen about the 50th day after the microcapsule administration. Following the first week of therapy, we observed in all patients a significant decrease in bone pain, improvement in urinary flow obstruction, and a reversal of the signs of prostatism. No side effects were observed, and acceptance of the microcapsules was very good. Our results show that a single dose of D-Trp-6-LH-RH microcapsules suppresses of the pituitary-testicular axis for at least 50 days. D-Trp-6-LH-RH microcapsules facilitate the treatment and should lead to an improvement in the therapeutic response.

No abstract